Table 3.
Clinical parameters, complement activation markers, and evolution in patients with malignant hypertension
| Patient | Clinical Parameters | Complement Parameters | Treatment and Evolution | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Pressure (mm Hg) | Hypertensive Retinopathya | Creatinine (0.3–1.3 mg/dl) | Platelets (130–400 109/L) | Hemoglobin (12–17 g/dl) | Lactate Dehydrogenase (<234 U/L) | Haptoglobin (0.3–1.8 g/L) | ADAMTS-13 Activity (%) | Serum C3 (0.8–1.9 g/L) | Serum C4 (0.1–0.5 g/L) | Serum 50% Hemolytic Complement (28–60 U/ml) | Activated-Plasma C5b-9 Deposits (Mean±SEM) | Anti-hypertensives drugs | Other Treatment | Response | Dialysis | |
| MH-1 | 180/95 | Grade 3 | 19.2 | 67 | 4.8 | 601 | 0.6 | 64 | 0.8 | 0.4 | 53.5 | 0.7±0.1 | 2 | No | No | Yes |
| MH-2 | 204/115 | Grade 3 | 38.8 | 76 | 6.9 | 833 | N.D. | 54 | 1.0 | 0.3 | 58 | 0.8±0.2 | 3 | No | Hematologic | Yes |
| MH-3 | 170/90 | Grade 4 | 23 | 110 | 8.3 | 384 | N.D. | 85 | 1 | 0.2 | 49.5 | 0.9±0.1 | 3 | Steroids; eculizumab | Hematologic | Yes |
| MH-4 | 240/170 | Grade 3 | 11.8 | 97 | 10.7 | 2095 | 0.01 | 46 | 1 | 0.3 | 54.5 | 0.6±0.2 | 2 | No | No | Yes |
| MH-5 | 190/120 | Grade 3 | 13.1 | 126 | 9.2 | 491 | 2.6 | N.D. | 1.4 | 0.4 | 57 | 1.1±0.1 | 5 | No | Hematologic | Yes |
ADAMTS-13, a disintegrin and metalloproteinase with thrombospondin motifs 13; MH-1, patient 1 with malignant hypertension; N.D., not done.
a
Hypertension-related retinopathy classification according to the classification of Keith, Wagener, and Barker (51).